Xiaoyu Xu

Xiaoyu Xu focuses her practice in the areas of initial public offerings, venture capital investment, mergers and acquisitions, and general corporate matters.

Xiaoyu is a native Mandarin speaker and is fluent in English.

Representative Matters:

Capital Markets

• Represented Keymed Biosciences in its US$400 million listing and global offering on the Main Board of the HKEX
• Represented Betta Pharmaceuticals in its proposed listing and global offering on the Main Board of the HKEX
• Represented Keymed Biosciences in its proposed listing and global offering on the Main Board of the HKEX
• Represented Jacobio Pharmaceuticals in its US$330 million listing and global offering on the Main Board of the HKEX
• Represented RemeGen in its US$515 million listing and global offering on the Main Board of the HKEX
• Represented Peijia Medical in its US$348 million listing and global offering on the Main Board of the HKEX
• Represented Fortune Financial Capital in the US$56.8 million listing and global offering of Zero2IPO Holdings on the Main Board of the HKEX
• Represented First Shanghai Capital Limited in the HK$550 million listing and global offering of Chen Lin Education Group Holdings Limited Board of the HKEX

Venture Capital Investments, Mergers & Acquisitions and Corporate Partnering & Licensing

• Represented InnoRNA in its global strategic collaboration with BeiGene to research and develop mRNA-LNP therapeutics 
• Represented Vivo Capital in forming a joint venture, Visirna Therapeutics, with Arrowhead Pharmaceuticals (Nasdaq: ARWAR) and subsequent license agreement for exclusive rights to develop and commercialize four of Arrowhead’s investigational RNA interference (RNAi) therapeutics for cardiometabolic diseases in Greater China
• Represented Bertelsmann Asia Investments in its multimillion Series A financing in Tantan Limited
• Represented Sequoia Capital and Gobi Partners in their US$15 million Series B financing in Cloudwise Technology
• Represented JAFCO Investment in its multimillion Series A financing in EasyPrint; and in its multimillion Series B financing in JianShi Technology
• Represented Demohour in its multimillion dollar Series A financing from Matrix Partners China
• Represented TTM Technologies Inc. on its US$550 million sales of mobility business unit consisting of four China manufacturing plants